BOLT · Bolt Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.70M | $7.69M | $7.88M | $5.73M | $231.0K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $28.53M | $57.47M | $61.54M | $73.12M | $40.36M |
| SG&A | $13.79M | $18.46M | $22.53M | $22.93M | $9.06M |
| Total Operating Expenses | $43.81M | $80.74M | $84.07M | $96.05M | $49.41M |
| D&A | $1.29M | $1.78M | $1.85M | $1.67M | $611.0K |
| Operating Income | ($36.11M) | ($73.05M) | ($76.20M) | ($90.32M) | ($49.18M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($33.38M) | ($63.12M) | ($69.20M) | ($88.10M) | ($60.73M) |
| EPS - Basic | ($17.85) | ($33.00) | ($36.60) | ($59.40) | - |
| EPS - Diluted | ($17.85) | ($33.00) | ($36.60) | ($59.40) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $11.70M | $7.21M | $10.81M | $9.24M | $27.38M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.44M | $1.51M | $2.99M | $3.59M | $3.57M |
| Current Assets | $30.26M | $50.81M | $105.71M | $172.75M | $189.16M |
| Total Assets | $56.75M | $99.63M | $159.78M | $227.81M | $307.72M |
| Current Liabilities | $8.44M | $15.86M | $20.46M | $23.12M | $21.33M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $30.24M | $42.43M | $47.04M | $56.30M | $57.60M |
| Stockholders' Equity | $26.50M | $57.20M | $112.74M | $171.51M | $250.12M |
| Retained Earnings | ($460.78M) | ($427.40M) | ($364.29M) | ($295.09M) | ($206.99M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($39.85M) | ($61.29M) | ($69.53M) | ($76.50M) | ($47.31M) |
| Investing Cash Flow | $44.30M | $57.58M | $71.04M | $57.86M | ($20.59M) |
| Financing Cash Flow | $19.0K | $108.0K | $253.0K | $503.0K | $39.60M |
| CapEx | $72.0K | $41.0K | $206.0K | $1.95M | $3.26M |
| Free Cash Flow | ($39.92M) | ($61.33M) | ($69.73M) | ($78.46M) | ($50.57M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -469.3% | -949.9% | -967.4% | -1576.6% | -21290.9% |
| EBITDA margin | -452.5% | -926.7% | -943.9% | -1547.5% | -21026.4% |
| Net margin | -433.7% | -820.8% | -878.6% | -1537.8% | -26289.2% |
| Free cash flow margin | -518.8% | -797.5% | -885.4% | -1369.5% | -21891.8% |
| FCF / Net income | 1.20 | 0.97 | 1.01 | 0.89 | 0.83 |
| R&D / Revenue | 370.8% | 747.3% | 781.4% | 1276.4% | 17470.6% |
| SG&A / Revenue | 179.3% | 240.0% | 286.1% | 400.2% | 3920.3% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -58.8% | -63.4% | -43.3% | -38.7% | -19.7% |
| Return on equity | -125.9% | -110.4% | -61.4% | -51.4% | -24.3% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 3.59 | 3.20 | 5.17 | 7.47 | 8.87 |
| Quick ratio | 3.59 | 3.20 | 5.17 | 7.47 | 8.87 |
| Cash ratio | 1.39 | 0.45 | 0.53 | 0.40 | 1.28 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 2.14 | 1.74 | 1.42 | 1.33 | 1.23 |
| Liabilities / Assets | 0.53 | 0.43 | 0.29 | 0.25 | 0.19 |
| Efficiency | |||||
| Asset turnover | 0.14 | 0.08 | 0.05 | 0.03 | 0.00 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 0.4x | 7.1x | 7.5x | 5.0x | - |
| P / S | 1.3x | 53.1x | 107.5x | 150.7x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 0.1% | -2.4% | 37.5% | 2380.1% | - |
| Revenue CAGR (3y) | 10.3% | 221.7% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 50.6% | 4.1% | 15.6% | -83.6% | - |
| Net income growth (YoY) | 47.1% | 8.8% | 21.5% | -45.1% | - |
| EPS growth (YoY) | 45.9% | 9.8% | 38.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 34.9% | 12.0% | 11.1% | -55.1% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -53.7% | -49.3% | -34.3% | -31.4% | - |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-8.08
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Bolt Biotherapeutics against the 5 most active filers in the same SIC group.